Patients deserve that clarity before a wellness trend hardens into an assumption
Structure and function of NAD kinase and NADP phosphatase: key enzymes that regulate the intracellular balance of NAD(H) and NADP(H)
Tirzepatide commonly causes nausea, vomiting, diarrhea, and decreased appetite, particularly during initiation and dose escalation
When choosing among them, factors such as glycemic efficacy, weight effects and patient preferences may take precedence over concerns about major differences in [GI] risk. She added clinicians should continue to monitor for GI symptoms, particularly early in treatment, as these events, while uncommon, remain more frequent than with some other diabetes drug classes. According to Alkabbani and colleagues, recent trials revealed that dulaglutide (Trulicity, Eli Lilly), semaglutide (Ozempic/Wegovy, Novo Nordisk) and tirzepatide (Zepbound, Eli Lilly) increased the risk for mild to serious GI adverse events like pancreatitis, constipation, nausea, vomiting and biliary disease